LLY Stock Recent News
LLY LATEST HEADLINES
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.
The U.S. Food and Drug Administration (FDA) recently announced that the shortage of Eli Lilly's weight loss medications, Mounjaro and Zepbound, has been resolved. While these drugs, which contain tirzepatide, are now more readily available, patients and prescribers might still face occasional local shortages as they move through the supply chain.
CNBC's Angelica Peebles joins 'Squawk on the Street' to report on Eli Lilly's new investment in a new $4.5 billion research and development center.
Eli Lilly and Co LLY is making a major move with a $4.5 billion investment to create the Lilly Medicine Foundry, a new research and manufacturing facility.
U.S. drugmaker Eli Lilly said on Wednesday it will invest $4.5 billion to create a new center for advanced manufacturing and drug development in Indiana.
Indiana facility will combine research, manufacturing and the latest technology to innovate new production methods and scale global access to clinical supply for Lilly's growing pipeline Opening in late 2027, the facility will increase Lilly's total capital commitment in the United States to more than $23 billion since 2020 INDIANAPOLIS , Oct. 2, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $4.5 billion investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development. This unique facility will give Lilly the ability to research new ways of producing medicines, while also scaling up manufacturing of medicines for clinical trials.
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Eli Lilly received FDA approval for Ebglyss for the treatment of moderate to severe atopic dermatitis this month. Ebglyss' efficacy looks comparable, if not slightly superior, to current market leader Dupixent. Ebglyss has launched successfully in Germany and Japan, and I expect the launch in the U.S. to go at least as well as Dupixent's launch in 2017.
Eli Lilly is making massive investments in manufacturing -- a key challenge now. The point of those investments is to produce enough of its drugs to meet demand.
Sylvia Jablonski, CEO of Defiance ETFs, talks about the Defiance Daily Target ETF (MSTX) that began public trading last month. She talks about why it's "a bang for your buck" for tactical traders.